Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al. · Journal of Clinical Oncology · 2007 · 2K citations

Medicine, Oncology, Pharmacology +14

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

Siegfried Segaert, Eric Van Cutsem · Annals of Oncology · 2005 · 574 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +16

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

Klaus J. Busam, Paola Capodieci, Robert J. Motzer et al. · British Journal of Dermatology · 2001 · 418 citations

Medicine, Dermatology, Oncology +16